Beacon's gene therapy for vision loss condition meets main trial goal

Beacon Therapeutics said on Monday its experimental gene therapy improved the ability to read in low-light ​conditions in a late-stage trial on people with ‌a form of inherited eye disease that can cause progressive vision loss.